Search

Your search keyword '"Myhr Eriksson, Kristina"' showing total 8 results
Start Over Author "Myhr Eriksson, Kristina" Search Limiters Full Text Publication Year Range Last 50 years Journal blood
8 results on '"Myhr Eriksson, Kristina"'

1. Effects of Dasatinib and Interferon-α Combination Treatment on the Immune System in CML

Author

Ilander, Mette, primary, Lähteenmäki, Hanna, additional, Olsson-Stromberg, Ulla, additional, Stentoft, Jesper, additional, Richter, Johan, additional, Koskenvesa, Perttu, additional, Höglund, Martin, additional, Dreimane, Arta, additional, Porkka, Kimmo, additional, Gedde-Dahl, Tobias, additional, Gjertsen, Björn T., additional, Gruber, Franz X., additional, Stenke, Leif, additional, Myhr-Eriksson, Kristina, additional, Markevärn, Berit, additional, Lubking, Anna, additional, Vestergaard, Hanne, additional, Udby, Lene, additional, Weis Bjerrum, Ole, additional, Hjorth-Hansen, Henrik, additional, and Mustjoki, Satu, additional

Published
2016
Full Text
View/download PDF

2. Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Author

Hjorth-Hansen, Henrik, primary, Stentoft, Jesper, additional, Richter, Johan, additional, Koskenvesa, Perttu, additional, Dreimane, Arta, additional, Porkka, Kimmo, additional, Gedde-Dahl, Tobias, additional, Gjertsen, Bjorn, additional, Gruber, Franz X., additional, Hoglund, Martin, additional, Lubking, Anna, additional, Myhr-Eriksson, Kristina, additional, Markevärn, Berit, additional, Vestergaard, Hanne, additional, Weis Bjerrum, Ole, additional, Stenke, Leif, additional, Mustjoki, Satu, additional, and Stromberg, Ulla, additional

Published
2015
Full Text
View/download PDF

3. Prevalence and Characteristics of Survivors from Adult Acute Myeloid Leukemia (AML) in Sweden 2014

Author

Juliusson, Gunnar, primary, Lazarevic, Vladimir, additional, Antunovic, Petar, additional, Derolf, Asa Rangert, additional, Garelius, Hege, additional, Lehmann, Sören, additional, Myhr-Eriksson, Kristina, additional, Möllgård, Lars, additional, Uggla, Bertil, additional, Wahlin, Anders, additional, Wennström, Lovisa, additional, and Höglund, Martin, additional

Published
2015
Full Text
View/download PDF

4. Improved Survival of Patients with Acute Myeloid Leukemia Following Implementation of Swedish National Guidelines: Results from the AML Registry 1997-2013

Author

Juliusson, Gunnar, primary, Lazarevic, Vladimir, additional, Lehmann, Sören, additional, Derolf, Åsa Rangert, additional, Möllgård, Lars, additional, Garelius, Hege, additional, Wennström, Lovisa, additional, Uggla, Bertil, additional, Antunovic, Petar, additional, Myhr-Eriksson, Kristina, additional, Wahlin, Anders, additional, and Höglund, Martin, additional

Published
2014
Full Text
View/download PDF

5. Allogeneic Transplantation in First Remission Improves Outcome in Secondary Acute Myeloid Leukemia

Author

Nilsson, Christer, primary, Hulegårdh, Erik, additional, Lazarevic, Vladimir, additional, Garelius, Hege, additional, Derolf, Asa Rangert, additional, Möllgård, Lars, additional, Wennström, Lovisa, additional, Uggla, Bertil, additional, Antunovic, Petar, additional, Myhr-Eriksson, Kristina, additional, Wahlin, Anders, additional, Höglund, Martin, additional, Juliusson, Gunnar, additional, Stockelberg, Dick, additional, and Soren, Lehmann, additional

Published
2014
Full Text
View/download PDF

6. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Author

Höglund, Martin, primary, Sandin, Fredrik, additional, Hellström, Karin, additional, Björeman, Mats, additional, Björkholm, Magnus, additional, Brune, Mats, additional, Dreimane, Arta, additional, Ekblom, Marja, additional, Lehmann, Sören, additional, Ljungman, Per, additional, Malm, Claes, additional, Markevärn, Berit, additional, Myhr-Eriksson, Kristina, additional, Ohm, Lotta, additional, Olsson-Strömberg, Ulla, additional, Själander, Anders, additional, Wadenvik, Hans, additional, Simonsson, Bengt, additional, Stenke, Leif, additional, and Richter, Johan, additional

Published
2013
Full Text
View/download PDF

7. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Author

Simonsson, Bengt, Gedde-Dahl, Tobias, Markevärn, Berit, Remes, Kari, Stentoft, Jesper, Almqvist, Anders, Björeman, Mats, Flogegård, Max, Koskenvesa, Perttu, Lindblom, Anders, Malm, Claes, Mustjoki, Satu, Myhr-Eriksson, Kristina, Ohm, Lotta, Räsänen, Anu, Sinisalo, Marjatta, Själander, Anders, Strömberg, Ulla, Bjerrum, Ole Weiss, Ehrencrona, Hans, Gruber, Franz, Kairisto, Veli, Olsson, Karin, Sandin, Fredrik, Nagler, Arnon, Nielsen, Johan Lanng, Hjorth-Hansen, Henrik, and Porkka, Kimmo

Abstract

Biologic and clinical observations suggest that combining imatinib with IFN-α may improve treatment outcome in chronic myeloid leukemia (CML). We randomized newly diagnosed chronic-phase CML patients with a low or intermediate Sokal risk score and in imatinib-induced complete hematologic remission either to receive a combination of pegylated IFN-α2b (Peg–IFN-α2b) 50 μg weekly and imatinib 400 mg daily (n = 56) or to receive imatinib 400 mg daily monotherapy (n = 56). The primary endpoint was the major molecular response (MMR) rate at 12 months after randomization. In both arms, 4 patients (7%) discontinued imatinib treatment (1 because of blastic transformation in imatinib arm). In addition, in the combination arm, 34 patients (61%) discontinued Peg–IFN-α2b, most because of toxicity. The MMR rate at 12 months was significantly higher in the imatinib plus Peg–IFN-α2b arm (82%) compared with the imatinib monotherapy arm (54%; intention-to-treat, P= .002). The MMR rate increased with the duration of Peg–IFN-α2b treatment (< 12-week MMR rate 67%, > 12-week MMR rate 91%). Thus, the addition of even relatively short periods of Peg–IFN-α2b to imatinib markedly increased the MMR rate at 12 months of therapy. Lower doses of Peg–IFN-α2b may enhance tolerability while retaining efficacy and could be considered in future protocols with curative intent.

Published
2011
Full Text
View/download PDF

8. A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.

Author

Simonsson, Bengt, Gedde-Dahl, Tobias, Markevärn, Berit, Remes, Kari, Stentoft, Jesper, Almqvist, Anders, Björeman, Mats, Flogegård, Max, Hallman, Heikki, Koskenvesa, Perttu, Lindblom, Anders, Malm, Claes, Mustjoki, Satu, Myhr-Eriksson, Kristina, Räsänen, Anu, Sinisalo, Marjatta, Sippola, Risto, Själander, Anders, Strömberg, Ulla, Bjerrum, Ole Weiss, Ehrencrona, Hans, Gruber, Franz, Kairisto, Veli, Olsson, Karin RN, Nagler, Arnon, Nielsen, Johan Lanng, Hjorth-Hansen, Henrik, and Porkka, Kimmo

Abstract

Imatinib mesylate (IM) 400 mg once daily (OD) is the current standard first-line therapy for CML. Several biological and clinical observations suggest that combining IM with interferon alpha (IFNa) may improve the outcome of treatment.To compare the effects of standard-dose IM to combination of IM and IFNa in newly diagnosed chronic phase CML patients with an intermediate or low Sokal risk score. The primary end point was to compare the major molecular response (MMR) rate after 12 months between the treatment arms (intention-to-treat analysis).In a Nordic CML Study Group (NMCLSG: Denmark, Finland, Norway and Sweden) and Israel multicenter study we randomized 114 newly diagnosed CML patients in complete hematological remission following 3 months of IM 400 mg OD induction therapy. The study arms were IM (Glivec, Novartis) and the combination of IM and IFNa 2b (PegIntron, Schering-Plough). IM dose was fixed at 400 mg OD. IFNa was started at 30 μg/week but could be escalated to 50 μg/week or reduced down to 15 μg/week depending on tolerability. Molecular response was evaluated by blood RQ-PCR for BCR-ABL1 and was expressed on the international scale (IS).As of August 17, 2009, 79 patients were evaluable for primary endpoint and 47 of these were in MMR (59%) The rate of complete cytogenetic response (CCgR) was 68/79 (86%). Nineteen patients (17%) were considered as treatment failures (grade 4 nonhematological adverse event, refusal, loss of CCgR, progression to advanced phase, protocol violation or other reason).A final analysis will be performed when we have complete data on all randomized patients. The comparison by treatment arm on molecular and cytogenetic responses as well as other relevant data (treatment failures, patients off-treatment for protocol violations, refusal or toxicity) will be presented on site.Supported by European LeukemiaNet, WP 4.Simonsson: Novartis: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding. BjÖreman:BMS: Consultancy, Honoraria. Mustjoki:BMS: Honoraria. StrÖmberg:Novartis: Honoraria; BMS: Honoraria. Weiss Bjerrum:Novartis: Consultancy, Honoraria; BMS: Consultancy, Honoraria. Gruber:Novartis: Research Funding. Nagler:Novartis: Consultancy. Porkka:Novartis: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results